A citation-based method for searching scientific literature

Erik J M van Bommel, Mark M Smits, Danique Ruiter, Marcel H A Muskiet, Mark H H Kramer, Max Nieuwdorp, Daan J Touw, Hiddo J L Heerspink, Jaap A Joles, Daniël H van Raalte. J Hypertens 2020
Times Cited: 3







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
66

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
242
66

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
66

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
300
66


Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation.
D O Verschure, B L F van Eck-Smit, G A Somsen, R J J Knol, H J Verberne. Neth Heart J 2016
8
33

Erythropoietin: repair of the failing heart.
Peter van der Meer, Erik Lipsic. J Am Coll Cardiol 2006
7
33

Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.
Amber L Beitelshees, Bruce R Leslie, Simeon I Taylor. Diabetes 2019
15
33

Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry.
Kenichiro Yamagata, Minoru Horie, Takeshi Aiba, Satoshi Ogawa, Yoshifusa Aizawa, Tohru Ohe, Masakazu Yamagishi, Naomasa Makita, Harumizu Sakurada, Toshihiro Tanaka,[...]. Circulation 2017
76
33

Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias.
Kathrin Weidner, Michael Behnes, Tobias Schupp, Jonas Rusnak, Linda Reiser, Armin Bollow, Gabriel Taton, Thomas Reichelt, Dominik Ellguth, Niko Engelke,[...]. Cardiovasc Diabetol 2018
7
33

Risk stratification after acute myocardial infarction by heart rate turbulence.
Petra Barthel, Raphael Schneider, Axel Bauer, Kurt Ulm, Claus Schmitt, Albert Schömig, Georg Schmidt. Circulation 2003
161
33

Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction.
Hoang V Tran, Joel M Gore, Chad E Darling, Arlene S Ash, Catarina I Kiefe, Robert J Goldberg. Cardiovasc Diabetol 2018
12
33

2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Ezra A Amsterdam, Nanette K Wenger, Ralph G Brindis, Donald E Casey, Theodore G Ganiats, David R Holmes, Allan S Jaffe, Hani Jneid, Rosemary F Kelly, Michael C Kontos,[...]. Circulation 2014
589
33

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
265
33

Frequency domain measures of heart period variability and mortality after myocardial infarction.
J T Bigger, J L Fleiss, R C Steinman, L M Rolnitzky, R E Kleiger, J N Rottman. Circulation 1992
33


Association of Genetic and Clinical Aspects of Congenital Long QT Syndrome With Life-Threatening Arrhythmias in Japanese Patients.
Wataru Shimizu, Hisaki Makimoto, Kenichiro Yamagata, Tsukasa Kamakura, Mitsuru Wada, Koji Miyamoto, Yuko Inoue-Yamada, Hideo Okamura, Kohei Ishibashi, Takashi Noda,[...]. JAMA Cardiol 2019
10
33


Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report.
Daisuke Matsutani, Masaya Sakamoto, Hiroyuki Iuchi, Souichirou Minato, Hirofumi Suzuki, Yosuke Kayama, Norihiko Takeda, Ryuzo Horiuchi, Kazunori Utsunomiya. Cardiovasc Diabetol 2018
21
33

Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2.
Vance B Matthews, Rosemary H Elliot, Caroline Rudnicka, Jana Hricova, Lakshini Herat, Markus P Schlaich. J Hypertens 2017
74
33

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar, James McLaren, Søren L Kristensen, David Preiss, John J McMurray. Diabetologia 2016
172
33


Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
A John Camm, Craig M Pratt, Peter J Schwartz, Hussein R Al-Khalidi, Maria J Spyt, Michael J Holroyde, Roger Karam, Edmund H Sonnenblick, Jose M G Brum. Circulation 2004
146
33

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Nannan Zhang, Bin Feng, Xuexing Ma, Kangyun Sun, Guidong Xu, Yafeng Zhou. Cardiovasc Diabetol 2019
25
33

Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.
Scott M Williams, Aikaterini Eleftheriadou, Uazman Alam, Daniel J Cuthbertson, John P H Wilding. Diabetes Ther 2019
25
33

Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack Trial.
Rachel Lampert, Jeannette R Ickovics, Catherine J Viscoli, Ralph I Horwitz, Forrester A Lee. Am J Cardiol 2003
104
33



SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Jürgen Woerle, Uli C Broedl, Odd Erik Johansen. Diab Vasc Dis Res 2015
246
33

Myocardial Ischemia Suppresses Ketone Body Utilization.
Yuichiro Arima, Yasuhiro Izumiya, Toshifumi Ishida, Seiji Takashio, Masanobu Ishii, Daisuke Sueta, Koichiro Fujisue, Kenji Sakamoto, Koichi Kaikita, Kenichi Tsujita. J Am Coll Cardiol 2019
8
33

Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction.
G Schmidt, M Malik, P Barthel, R Schneider, K Ulm, L Rolnitzky, A J Camm, J T Bigger, A Schömig. Lancet 1999
488
33

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Hiroto Oshima, Takayuki Miki, Atsushi Kuno, Masashi Mizuno, Tatsuya Sato, Masaya Tanno, Toshiyuki Yano, Kei Nakata, Yukishige Kimura, Koki Abe,[...]. J Pharmacol Exp Ther 2019
29
33



Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report.
Shunsuke Kiuchi, Shinji Hisatake, Takayuki Kabuki, Takahiro Fujii, Takashi Oka, Shintaro Dobashi, Hidenobu Hashimoto, Takanori Ikeda. Drug Discov Ther 2018
10
33

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
498
33

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale.
Yoshiaki Kubota, Takeshi Yamamoto, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yuki Iwasaki, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto,[...]. Diabetes Ther 2018
16
33

The spectrum of epidemiology underlying sudden cardiac death.
Meiso Hayashi, Wataru Shimizu, Christine M Albert. Circ Res 2015
230
33

Comparison of late potentials for 24 hours between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy using a novel signal-averaging system based on Holter ECG.
Atsuko Abe, Kenzaburo Kobayashi, Hitomi Yuzawa, Hideyuki Sato, Shunji Fukunaga, Tadashi Fujino, Yoshifumi Okano, Junichi Yamazaki, Yosuke Miwa, Hideaki Yoshino,[...]. Circ Arrhythm Electrophysiol 2012
17
33

Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice.
Yumiko Chiba, Tetsuya Yamada, Sohei Tsukita, Kei Takahashi, Yuichiro Munakata, Yuta Shirai, Shinjiro Kodama, Yoichiro Asai, Takashi Sugisawa, Kenji Uno,[...]. PLoS One 2016
30
33


Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.
Ioanna Andreadou, Panagiotis Efentakis, Evangelos Balafas, Gabriele Togliatto, Constantinos H Davos, Aimilia Varela, Constantinos A Dimitriou, Panagiota-Efstathia Nikolaou, Eirini Maratou, Vaia Lambadiari,[...]. Front Physiol 2017
60
33

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Patrick T O'Gara, Frederick G Kushner, Deborah D Ascheim, Donald E Casey, Mina K Chung, James A de Lemos, Steven M Ettinger, James C Fang, Francis M Fesmire, Barry A Franklin,[...]. Circulation 2013
33



Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
171
33

Identification of high-risk Brugada syndrome patients by combined analysis of late potential and T-wave amplitude variability on ambulatory electrocardiograms.
Koichiro Yoshioka, Mari Amino, Wojciech Zareba, Makiyoshi Shima, Atsushi Matsuzaki, Toshiharu Fujii, Shigetaka Kanda, Yoshiaki Deguchi, Yoshinori Kobayashi, Yuji Ikari,[...]. Circ J 2013
26
33

24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
Kazuomi Kario, Kenta Okada, Mitsutoshi Kato, Masafumi Nishizawa, Tetsuro Yoshida, Tsuguyoshi Asano, Kazuaki Uchiyama, Yawara Niijima, Tomohiro Katsuya, Hidenori Urata,[...]. Circulation 2018
75
33

Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Ruth L Coleman, Alastair M Gray, Uli C Broedl Md, David Fitchett, Jyothis T George, Hans J Woerle, Bernard Zinman, Rury R Holman. Diabetes Obes Metab 2020
6
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.